November 11, 2016 11:06 AM ESTUpdated 11:23 AM
News Briefing

Bris­tol-My­ers part­ners with Johns Hop­kins on Op­di­vo pact; A Valeant by any oth­er name…

Shehla Shakoor

Managing Director

Johns Hop­kins sci­en­tists will go to work study­ing Bris­tol-My­ers Squibb’s Op­di­vo and Yer­voy, look­ing for their weak points as the com­pa­ny looks to im­prove …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times